Compare TOI & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOI | CTKB |
|---|---|---|
| Founded | 2007 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.1M | 433.8M |
| IPO Year | N/A | 2021 |
| Metric | TOI | CTKB |
|---|---|---|
| Price | $3.12 | $5.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $6.00 | $5.88 |
| AVG Volume (30 Days) | ★ 3.1M | 1.9M |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $461,039,000.00 | $196,828,000.00 |
| Revenue This Year | $21.71 | N/A |
| Revenue Next Year | $20.58 | $7.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.67 | N/A |
| 52 Week Low | $0.15 | $2.37 |
| 52 Week High | $4.88 | $7.30 |
| Indicator | TOI | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 39.14 | 66.53 |
| Support Level | $2.88 | $5.15 |
| Resistance Level | $3.32 | $5.95 |
| Average True Range (ATR) | 0.35 | 0.43 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 19.12 | 66.15 |
The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.